Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
opaviraline
- Development stage
- Discontinued
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Opaviraline is a small molecule non-nucleoside reverse transcriptase inhibitor (NNRTI) that was developed for the treatment of HIV infections. It acts by inhibiting the activity of HIV reverse transcriptase, thereby blocking viral replication. The drug reached phase II clinical trials in Germany, South Africa, and the United Kingdom but development was discontinued and it is not marketed. Opaviraline displays time-dependent pharmacokinetics with a relatively long plasma half-life suitable for once-daily dosing[2][4][5][7].
- Other names
- opaviralinaOpaviraline [INN]178040-94-3
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on opaviraline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on opaviraline.